Abstract
Recently, Siemens Diagnostics released a new calcium assay (CA_2) based on complex formation of calcium with Arsenazo III dye for use on the three automated, random access ADVIA Chemistry analyzers (1650, 2400, and 1200). We evaluated this method for analytical performance as well as potential interference from gadolinium‐containing magnetic contrast agents. With Siemens Chemistry serum and urine controls, 2‐levels each, the imprecision for the new method was (n=40 each): within‐run and total CV of <2.2 and <3.8%, respectively, over all three platforms. The analytical range/linearity of the method (all three systems) was 1–16 mg/dl (serum or plasma) and 1–32 mg/dl (urine). The new method on all three platforms correlated well with a reference (Inductively Coupled Plasma Atomic Emission Spectroscopy) method (n=61, range 4.03–10.30 mg/dl). The ADVIA 1650 CA_2 method also correlated well with the Roche Modular system® Calcium method. The new method showed <10% interference with unconjugated or conjugated bilirubin (50 mg/dl), hemoglobin (1,000 mg/dl), lipids (1,000 mg/dl), and two magnetic resonance contrast agents containing Gadolinium (OptiMARK® 1 mmol/l and Omniscan 1.5 mmol/l). On the contrary, the Roche Calcium method showed significant negative interference with gadolinium‐containing contrast agents. We conclude that the ADVIA Ca_2 method can measure serum, plasma, or urine calcium concentrations accurately and is also free from interferences of gadolinium‐containing agents. J. Clin. Lab. Anal. 23:399–403, 2009. © 2009 Wiley‐Liss, Inc.
Keywords: calcium, ADVIA, interference, gadolinium
REFERENCES
- 1. Pecherstorfer M, Brenner K, Zojer N. Current management stratigies for hypercalcemia. Tret Endocrinol 2003;2:273–292. [DOI] [PubMed] [Google Scholar]
- 2. Lumachi F, Brunello A, Roma A, Basso U. Cancer induced hypercalcemia. Anticancer Res 2009;29:1551–1555. [PubMed] [Google Scholar]
- 3. Lumachi F, Brunello A, Roma A, Basso U. Medical management of malignancy‐associted hypercalcemia. Curr Med Chem 2008;15:415–421. [DOI] [PubMed] [Google Scholar]
- 4. Medarov BI. Milk‐alkali syndrome. Mayo Clinica Proc 2009;84:261–267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Robertson WG, Marshall RW. CRC Crit. Rev Clin Lab Sci 1979;11:271–304. [DOI] [PubMed] [Google Scholar]
- 6. Zak B, Epstien E, Baginski ES. Review of calcium methodologies. Ann Clin Lab Sci 1975;5:195–215. [PubMed] [Google Scholar]
- 7. Hartmann AE, Lewis LR. Evaluation of the ASTRA‐O‐cresolpthalein complexone calcium method. Am J Clin Pathol 1984;82:182–187. [DOI] [PubMed] [Google Scholar]
- 8. Janssen JW, Helbing AR. Arsenazo III: an improvement of the routine calcium determination in serum. Eur J Clin Chem Clin Biochem 1991;29:197–201. [PubMed] [Google Scholar]
- 9. Proctor KA, Rao LV, Roberts WL. Gadolinium magnetic resonance contrast agents produce analytical interference in multiple serum assays. Am J Clin Pathol 2004;121:282–292. [DOI] [PubMed] [Google Scholar]
- 10. Emerson J, Kost G. Spurious hypocalcemia after Omniscan or OptiMark enhanced magnetic resonance imaging: an algorithm for minimizing a false positive laboratory value. Arch Pathol Lab Med 2004;128:1151–1156. [DOI] [PubMed] [Google Scholar]
- 11. Kang HP, Scott MG, Joe BN, et al. Model for predicting the impact of gadolinium on plasma calcium measured by teh O‐cresolphthalein method. Clin Chem 2004;50:741–746. [DOI] [PubMed] [Google Scholar]
- 12. Gandhi M, Narra VR, Brown JJ, et al. Clinical and economic impact of falsely decreased calcium values caused by gadoversetamide interference. Am J Roentgenol 2008;190:W213–W217. [DOI] [PubMed] [Google Scholar]
- 13. Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia. Radiology 2003;227:639–646. [DOI] [PubMed] [Google Scholar]
- 14. Lin J, Idee JM, Port ME, et al. Interference of magnetic resonance contrast agents with serum calcium measurement technique using colorimetric reagents. J Pharm Biomed Anal 1999;21:931–943. [DOI] [PubMed] [Google Scholar]
- 15. Lowe A, Balzer T, Hirt U. Interference of gadolinium containing contrast enhancing agents with colorimetric calcium laboratory testing. Invest Radiol 2005;40:521–525. [DOI] [PubMed] [Google Scholar]
- 16. Normann PT, Froysa A, Svaland M. Interference of gadodiamide injection (OMNISCAN) on the colorimetric determination on serum calcium. Scand J Clin Lab Invest 1995;55:421–426. [DOI] [PubMed] [Google Scholar]